CollPlant Biotechnologies (CLGN) Cash from Investing Activities (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Cash from Investing Activities came in at -$15000.0 in Q4 2025, up 74.14% YoY from -$8613.9 in Q4 2024, and down 1400.0% on a QoQ basis from -$1000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Cash from Investing Activities (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Cash from Investing Activities data on file, last reported at -$15000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 74.14% year-over-year to -$15000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$77000.0 (up 85.71% YoY) and the FY2025 annual result came in at -$27000.0, up 94.99% from the prior year.
- Cash from Investing Activities eased to -$15000.0 in Q4 2025, from -$1000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $29.9 million in Q1 2022 to a low of -$31.6 million in Q4 2021.
- A 5-year average of -$1.3 million and a median of -$243000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 7194.7% in 2021, down 35404.71% in 2021.
- Tracing CLGN's Cash from Investing Activities over 5 years: stood at -$31.6 million in 2021, then surged by 99.04% to -$304000.0 in 2022, then retreated by 22.37% to -$372000.0 in 2023, then surged by 84.41% to -$58000.0 in 2024, then jumped by 74.14% to -$15000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$15000.0 (Q4 2025), -$1000.0 (Q3 2025), and -$3000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Dec 31, 2024 | -58,000.00 |
| Dec 31, 2024 | -58,000.00 |
| Sep 30, 2024 | -140,000.00 |
| Sep 30, 2024 | -140,000.00 |
| Jun 30, 2024 | -259,000.00 |
| Jun 30, 2024 | -259,000.00 |
| Mar 31, 2024 | -82,000.00 |
| Mar 31, 2024 | -82,000.00 |
| Dec 31, 2023 | -372,000.00 |
| Dec 31, 2023 | -372,000.00 |
| Sep 30, 2023 | -243,000.00 |
| Sep 30, 2023 | -243,000.00 |
| Jun 30, 2023 | -396,000.00 |
| Jun 30, 2023 | -396,000.00 |